
PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test
FOR IMMEDIATE RELEASE
SANTA ANA, Calif., July 16, 2025 – PHASE Scientific International, a leading innovator in diagnostic solutions, today announced a significant expansion of its INDICAID® respiratory portfolio with the exclusive U.S. launch of the novel FebriDx® test. This groundbreaking diagnostic tool is set to enhance the management of respiratory infections by providing rapid, simultaneous detection of key viral and bacterial pathogens directly at the point of care.
The FebriDx® test represents a substantial advancement in diagnostic capabilities for healthcare providers. It is designed to differentiate between viral and bacterial respiratory infections, offering crucial information to guide appropriate treatment decisions. This capability is particularly vital in combating antibiotic resistance, a growing global health concern, by helping clinicians to avoid unnecessary antibiotic prescriptions for viral illnesses.
The INDICAID® platform, renowned for its ease of use and efficiency, now welcomes FebriDx® to its comprehensive suite of diagnostic tests. This integration further strengthens PHASE Scientific’s commitment to delivering accessible and accurate diagnostic solutions that improve patient outcomes and streamline healthcare workflows.
“We are thrilled to introduce the FebriDx® test to the U.S. market through our INDICAID® portfolio,” said [Name and Title of a PHASE Scientific Executive, if available, otherwise use a general statement like “a spokesperson for PHASE Scientific”]. “FebriDx® addresses a critical need for rapid, multiplexed diagnostics in the management of respiratory infections. Its ability to quickly distinguish between viral and bacterial causes of fever and respiratory symptoms will empower healthcare professionals to make more informed decisions, leading to better patient care and contributing to responsible antibiotic stewardship.”
The FebriDx® test utilizes advanced immunoassay technology to detect antigens from common respiratory pathogens. The results are available within minutes, allowing for immediate clinical action. This rapid turnaround time is invaluable in busy clinical settings, enabling faster patient disposition and reducing the potential for disease transmission.
The expansion of the INDICAID® respiratory portfolio with the addition of FebriDx® underscores PHASE Scientific’s dedication to innovation and its ongoing efforts to support public health. By providing clinicians with the tools they need to effectively diagnose and manage respiratory illnesses, the company aims to contribute to a healthier future for communities across the United States.
About PHASE Scientific International:
PHASE Scientific is a biotechnology company dedicated to developing innovative diagnostic solutions that improve patient care and public health. Through its advanced technology platforms, including INDICAID®, PHASE Scientific provides accessible, accurate, and rapid diagnostic tests for a range of critical health conditions. The company is committed to empowering healthcare professionals with the information they need to make timely and effective treatment decisions.
About FebriDx®:
FebriDx® is a novel point-of-care diagnostic test designed for the rapid, simultaneous detection of key viral and bacterial respiratory pathogens. It aids in the differential diagnosis of respiratory infections, assisting healthcare providers in guiding appropriate treatment strategies.
Contact:
[Insert Contact Information Here – e.g., Media Relations Department, PHASE Scientific International] [Email Address] [Phone Number]
###
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test’ at 2025-07-16 00:44. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.